Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients. Cancer biopsies are generally performed when cancer is diagnosed and are sometimes repeated when the cancer is suspected to have spread but this is not mandatory. However, studies have shown that cancers change with time and evolve to become resistant to therapy. The purpose of this study is to assess the feasibility of biopsies of multiple cancer sites across different time points during treatment and understand how cancers evolve and change throughout treatment. The findings of this study could pave the way for using cancer biopsies more frequently in the clinic to pick up changes in cancer behaviour that could influence treatment choice. The samples collected from this study will be used for molecular and genetic research to increase our understanding of how metastatic breast cancer changes during treatment and will enable us to develop new cancer treatments and new ways of monitoring response to cancer therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak piersi, którego nie można operować lub który dał przerzuty, albo podejrzenie nawrotu poprzednio leczonego raka piersi z przerzutami do innych tkanek.
- •Osoby w wieku 18 lat lub starsze.
- •Wyrażenie pisemnej zgody na udział w badaniu.
✗ Disqualifies
- •Przerzuty ograniczone tylko do kości, bez zajęcia tkanek miękkich.
- •Problemy z krwawieniem lub przyjmowanie leków rozrzedzających krew, które uniemożliwiają bezpieczne pobranie wycinka.
- •Lekarz prowadzący oceni, że ryzyko związane z pobraniem wycinka jest zbyt duże (większe niż 1% ryzyka poważnych komplikacji).
- •Stan ogólny pacjenta oceniony jako bardzo zły (tzw. performance status 3 lub wyższy).
- •Znane, przewlekłe choroby zakaźne (np. zapalenie wątroby typu B i C, HIV), które mogą wpływać na bezpieczeństwo pacjenta.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 12, 2026
- Sex
- No restrictions
Locations (1)
Royal Marsden NHS Foundation Trust
London, United Kingdom
Trial contact
Sophie Cooke
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.